

STATISTICAL METHODS FOR MERGING GEO-SPATIAL MAPS AND TRANSMISSION MODELS

Panayiota Touloupou¹, Simon Spencer² and Deirdre Hollingsworth³

¹School of Mathematics, University of Birmingham

² Department of Statistics, University of Warwick

³ Oxford Big Data Institute, University of Oxford

Geo-Spatial maps: Lancaster, LSHTM

LF models: Oxford/Warwick/Surrey/Birmingham, Erasmus MC, Notre Dame

ModStatSAP
INRAE, France
06 July, 2021



UNIVERSITY OF
BIRMINGHAM



Introduction

Linking Maps with Models

Applications

Discussion

Introduction



Introduction

- **Geo-spatial maps** of disease prevalence are useful for guiding the planning of reliable spatial control programmes.
- **Mathematical models** can predict the progression of an epidemic \implies evaluate potential intervention strategies.
- However, mathematical modelling frequently **ignores spatial heterogeneity**.


Objectives:

- Develop a method for linking transmission models and geo-spatial maps.
- **Key feature:** Appropriately estimating and communicating the projections with their uncertainty.

Linking Maps with Models




Survey Data



Geostatistical
analysis





Geo-Spatial Map






Survey Data



Geostatistical analysis





Geo-Spatial Map






Survey Data



Geostatistical analysis




Geo-Spatial Map






Prevalence And Population Data





Methodology: Illustration





Weight The Simulations: Algorithm¹

For pixel i and simulation j :

- Calculate:

$$w_{ij}^{(1)} = \pi_i(\boldsymbol{\theta}_j)/q(\boldsymbol{\theta}_j),$$

where $\pi_i(\boldsymbol{\theta})$ is the prior on the model parameters $\boldsymbol{\theta}$ and $q(\boldsymbol{\theta})$ is the proposal distribution over the parameter space.

- Reweigh the simulations to match pixel prevalence distributions:

$$w_{ij}^{(2)} = \frac{f(p_j|\mathbf{d}_i)}{g(p_j|\mathbf{w}_i^{(1)})} w_{ij}^{(1)},$$

where $\mathbf{d}_i = (d_{i1}, \dots, d_{iM})$ is the posterior samples of prevalences and p_j prevalence of simulation j .


- No closed form \implies Empirical alternatives.

¹Panayiota Touloupou et al. “Statistical methods for linking geostatistical maps and transmission models: Application to lymphatic filariasis in East Africa”. In: *Spatial and Spatio-temporal Epidemiology* (2020), p. 100391.




Weight The Simulations: Illustration

Observed Prevalence




Simulated Prevalence






Weight The Simulations: Illustration

Observed Prevalence



Weighted Prevalence



Applications



Lymphatic Filariasis (LF) In Africa


- Lymphatic filariasis (also known as elephantiasis) is a parasitic disease caused by filarial worms.
- Vector borne, transmitted by mosquitoes.
- Global efforts for LF elimination as a public health problem:
 - Prevalence < 1%.
- Use of Mass Drug Administration (MDA).
- New guidelines for 2030.
- **Aim:** Inform policy where elimination efforts should be focused.






Application 1: LF In Ethiopia

Predictive mean MF Prevalence



(a) Geo-spatial map provided by Emanuele Giorgi (pixel scale 5km²).


Log population (pixel scale 5km²)



(b) Worldpop population estimates.




Predictive mean MF Prevalence




(c) Geo-spatial map provided by Emanuele Giorgi (pixel scale 5km²).


ITN coverage 2014



(d) Extracted from the Malaria Atlas Programme (Jorge Cano).



(e) Pixel Groups.



(f) Historic MDA.






Future Intervention Strategies

- In the case of LF Ethiopia is advised to perform Mass Drug Administration (MDA), Ivermectin (IVM) + Albendazole (ALB) with 65% coverage, once a year.
- We tested 4 future intervention strategies:
 1. No intervention or if already started complete 5 rounds of MDA.
 2. MDA with 65% coverage, once a year for unlimited rounds.
 3. MDA with 80% coverage, once a year for unlimited rounds.
 4. MDA with 65% coverage, twice a year for unlimited rounds.
- Different groups have various backgrounds of historical treatments, ie. MDA and/or bed-nets → **104 scenarios**.
- We consider 3 different models for LF in Ethiopia:
 - TRANSFIL (University of Warwick).
 - EPIFIL (University of Notre Dame).
 - LYMFASIM (Erasmus MC).






Geo-Spatial Maps Of Prevalence






Estimated TRANSFIL Maps Of Prevalence






Forecast Current Strategy: IU level


TRANSFIL model




LYMFASIM model



EPIFIL model




Forecast with current strategy






Predicted Year Of Elimination






Application 2: LF In Africa

Parasitological




Serological






Application 2: LF In Africa



(a) Pre-control geo-spatial map provided by Claudio Fronterre (pixel scale 5km²).



(b) ESPEN's historic MDA interventions provided by Jorge Cano.



- Geographical data:
 - **Historic MDA** interventions: gap between reported and true coverage (we considered 0%, 15% or 65%).
 - **Bed-net coverage** for each year, extracted from the Malaria Atlas Programme (we considered 0%, 25%, 50% or 75%).
 - WorldPop **population data**.
- We considered **4 future intervention strategies**:
 1. No intervention,
 2. WHO guidelines specified for each region for unlimited rounds,
 - Annual Ivermectin (IVM) + Albendazole (ALB) with 65% coverage
 - Annual Diethylcarbamazine (DEC) + ALB with 65% coverage
 - Biannual ALB with 65% coverage
 - Annual IVM + DEC + ALB with 65% coverage
 3. Increased coverage for unlimited rounds,
 4. Increased frequency for unlimited rounds.



- Different regions have various backgrounds of historical treatments, ie. MDA and/or bed-nets:
 - **2611 total number of scenarios.**
- We consider 3 different models for LF in Africa:
 - **TRANSFIL** (Warwick/Oxford),
 - **LYMFASIM** (Erasmus MC),
 - **EPIFIL** (Notre Dame).
- Ensemble model.




Impact Of Current Interventions


Thanks to **Claudio Fronterre** for the video and for all the remaining figures!!!



Impact Of Current Interventions



(a) Pre-control prevalence.







(b) Prevalence at 2018.



Impact Of Future Interventions



Projected Year Of Elimination



Discussion



Conclusions:

- Bayesian methodology that integrates the uncertainty over multiple sources.
- Method reproduces spatial maps of disease prevalence well and carefully propagates uncertainty forward in time.
- Methodology can readily applied to different models/diseases.
- Evaluate impact of current and future intervention strategies.

Future work:

- Combine simulations from multiple models: Model comparison?
- Transmission assessment survey (TAS) data: We can use the TAS data for model validation.
- Gap between reported and true coverage.
- Weaknesses of our approach: Independent pixels.



Conclusions:

- Bayesian methodology that integrates the uncertainty over multiple sources.
- Method reproduces spatial maps of disease prevalence well and carefully propagates uncertainty forward in time.
- Methodology can readily applied to different models/diseases.
- Evaluate impact of current and future intervention strategies.

Future work:

- Combine simulations from multiple models: Model comparison?
- Transmission assessment survey (TAS) data: We can use the TAS data for model validation.
- Gap between reported and true coverage.
- Weaknesses of our approach: Independent pixels.



Acknowledgement

- Simon Spencer (Warwick)
- Joaquin Prada (Surrey)
- Déirdre Hollingsworth (Oxford)
- Mike Irvine (BCCDC)
- Paul Brown (Warwick)

- Claudio Fronterre (Lancaster)
- Emanuele Giorgi (Lancaster)
- Rachel Pullan (LSHTM)
- Jorge Cano (LSHTM)

- Periklis Kontoroupis (Erasmus MC)
- Johanna Munoz Avila (Erasmus MC)
- Wilma Stolk (Erasmus MC)
- Sake de Vlas (Erasmus MC)

- Edwin Michael (Notre Dame)
- Morgan Smith (Notre Dame)
- Swarnali Sharma (Notre Dame)



BILL & MELINDA
GATES *foundation*

NTD
MODELLING
CONSORTIUM

